Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

and diluted

40,916,66632,828,69737,417,77522,909,802ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanyBALANCE SHEET DATA(unaudited)(in thousands except share amounts)December 31,
2011December 31,
2010Cash and cash equivalents

$
5,624$
40,030Short term investments

$
,746$
23,351Total assets

$
9,493$
5,263Total current liabilities, excluding current portion of notes payable

$
26,078$
8,005Total notes payable

$
24,331$
8212;Deficit accumulated during development stage

$   (200,979)$   (105,644)Total shareholders' equity

$
9,084$
57,258Common shares outstanding

40,933,35432,853,032
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
(Date:9/30/2014)... , Sept. 30, 2014 BioStructures, LLC ... American Association of Tissue Banks (AATB), it was ... Executive Officer. Accreditation follows an intensive ... specially trained AATB inspector.  It establishes that the ... the facility meets or exceeds the standards set ...
(Date:9/30/2014)... , Sept. 30, 2014  Proteomics is a ... a new report from Kalorama Information.  The healthcare market ... occurred in proteomics in the past two years.  ... agreements between private proteomic companies and academic institutions, ... novel proteomics innovator companies.  Kalorama observed the industry ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Biostructures, LLC Earns AATB Accreditation 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 2Report: Race for Proteomics Knowledge Spurs Investment and Partnerships 3
(Date:9/30/2014)... Maryland-led research team has been awarded a three-year ... Health (NIH) to develop new imaging technologies and ... of how large networks of neurons in the ... will help researchers identify the precise interactions between ... decision-making and speaking, and alterations in these interactions ...
(Date:9/30/2014)... Charlotte, N.C. (PRWEB) September 30, 2014 ... as an option to help diabetics curb their sweet ... journal Nature this September, suggests that zero-calorie ... for type 2 diabetes. , The Weizmann Institute ... when they fed artificial sweeteners to mice, the mice ...
(Date:9/30/2014)... FL (PRWEB) September 30, 2014 Regenerative ... to two new clinics in Nashville, Tennessee. RMS welcomes ... Apnea Institute, and the expansion of a new treatment ... introduction of the Sleep Apnea Institute to Nashville, the ... suffer from sleep apnea: both diagnosed and undiagnosed. With ...
(Date:9/30/2014)... -- Medicare should cover low-dose computed tomography lung cancer ... a coalition of more than 60 patient and medical ... Cancer Alliance, the Society of Thoracic Surgeons, the American ... American Society of Clinical Oncology, made its point in ... Medicare & Medicaid Services (CMS). Such screening reduces ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacyā€¯ (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... ... tidbits people are learning about their ancestors is not just trivia. This information is highly ... understanding their familial and ancestral past. , ... Doylestown, PA (PRWEB) March 13, 2010 -- Noted author Donna Evans Strauss ...
... (Nasdaq: SIAL ) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small ... ... , , ... ...
... 19 year olds and to those currently not in employment in a bid to increase awareness of safety at work. , ... , , ... ... ...
... 15, 2010 The Autism Consortium, an innovative research, ... enhancing clinical care for families with autism spectrum disorders ... study of genetic testing methods for autism spectrum disorders ... early online release in their eFirst pages today and ...
... AllegroMedical.com, ... meaning that just under 13 years, it has served more than a million customers nationwide. ... (Vocus) March 14, 2010 ... website launched in 1997. The first company to sell medical supplies online, it has grown ...
... its kind to date using cardiac computed tomography angiography, ... coronary artery disease are at higher risk of developing ... Henry Ford Hospital researchers say. Researchers analyzed the ... computed tomography angiography and found that those with a ...
Cached Medicine News:Health News:Author Proves What Celebrities are Learning in "Who Do You Think You Are?" is More Important Than They Realize 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 2Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 3Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 4Health News:Sigma-Aldrich Reaches Agreement to Sell Pfizer's Bioactive Small Molecule Compounds 5Health News:British Safety Council Offers Free Health and Safety Qualifications 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 2Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 3Health News:Autism Consortium study in Pediatrics shows CMA finds more genetic abnormalities than current tests 4Health News:Online Medical Supplies Superstore Ships 1 Millionth Order 2Health News:Family history is strong predictor of obstructive coronary artery disease using CCTA 2
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
... It's easy on delicate ... design and hydrophilic coating provide ... lubricating gel. It's easy to ... the catheter with its own ...
... line of Personal Catheters® ... you would choose for ... configurations - standard, antibacterial, ... - are based on ...
... Medical's line of Personal ... catheters you would choose ... product configurations - standard, ... hydro - are based ...
Medicine Products: